Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — VialBase Research

Summary

SURMOUNT-OSA evaluated tirzepatide for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The trial demonstrated significant reductions in the apnea-hypopnea index (AHI) alongside substantial weight loss, positioning tirzepatide as a potential treatment for obesity-related OSA.

Key Findings

• Tirzepatide reduced AHI (apnea-hypopnea index) by approximately 50-60% vs placebo
• Meaningful proportion of patients had AHI reduced below the moderate OSA threshold
• Mean weight loss of approximately 18-20% accompanying AHI improvements
• Improvements in oxygen desaturation index and sleep quality measures
• Positions GLP-1/GIP agonists as treatment for obesity comorbidities beyond weight alone
• CPAP usage requirements potentially reduced in some patients

Methodology

Phase 3, double-blind, placebo-controlled RCT. 469 adults with BMI ≥30 and moderate-to-severe OSA (AHI ≥15). Two studies: Study 1 included patients not using CPAP; Study 2 included patients using CPAP at baseline. 52-week treatment with tirzepatide (10 or 15mg) vs placebo.

Limitations

• OSA measurement can be variable night-to-night
• Weight loss alone (via any method) would be expected to improve OSA
• Does not establish whether tirzepatide has OSA-specific effects independent of weight loss
• Long-term OSA outcomes and cardiovascular impact not assessed
• CPAP remains the standard of care with stronger evidence base

Relevance to Content

Expands the tirzepatide narrative beyond weight loss to sleep health — a major consumer pain point. Content opportunity to discuss obesity as a systemic condition affecting sleep, cardiovascular risk, and quality of life. Useful for articles targeting the sleep apnea population as a tirzepatide audience.

See Also

• Parent compound: Tirzepatide